Mario F. Mendez

Dr. Mario F. Mendez


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Dementia and Geriatric Cognitive Disorders
Verified
Journal Article
Closed access
PDF file
MMMario F. Mendez
Mario F. Mendez
MGMehdi Ghajarania
Mehdi Ghajarania
KPKent M. Perryman
Kent M. Perryman
Background: Predominant and progressive complex visual disorders are often due to posterior cortical atrophy (PCA), a rare early-onset dementing syndrome presenting with visual complaints. In clinicopathological studies, PCA is most commonly considered a form of Alzheimer’s disease (AD); no prior study has evaluated clinical differences between PCA and AD. Methods: This study identified 15 patients who presented with progressive complex visual disorders and predominant occipitoparietal hypoperfusion on SPECT. These patients were retrospectively compared on clinical variables with 30 patients with clinically probable AD matched for gender, age and duration of illness. Results: The PCA patients presented with alexia, elements of Balint’s syndrome, apperceptive visual agnosia, dressing apraxia and environmental disorientation along with elements of Gerstmann’s syndrome. Compared to the AD patients, the 15 PCA patients (mean age of onset 58 years, range 51–64) had significantly better verbal fluency, less memory difficulty, more depression and greater insight into their illness but similar familial and apolipoprotein E risk factors. In the PCA patients, MRI often showed occipitoparietal atrophy without detectable mesiotemporal atrophy. Conclusions: PCA is a distinct clinical syndrome and not just AD with prominent visual deficits. Compared to AD controls, PCA patients have better language and memory but more insight and depression and more posterior atrophy on MRI. These results indicate clinical criteria for the diagnosis of PCA and recommend specific interventions such as visual aids and antidepressant medications. Similar risk factors and course suggest that PCA is most commonly an early-onset posteriorly shifted AD variant.

1 February 2019 in Continuum
Verified
Journal Article
Closed access
MMMario F. Mendez
Mario F. Mendez
NDINGS Early-onset AD comprises about 5% to 6% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics of early-onset AD in comparison to late-onset AD include a larger genetic predisposition (familial mutations and summed polygenic risk), more aggressive course, more frequent delay in diagnosis, higher prevalence of traumatic brain injury, less memory impairment and greater involvement of other cognitive domains on presentation, and greater psychosocial difficulties. Neuroimaging features of early-onset AD in comparison to late-onset AD include greater frequency of hippocampal sparing and posterior neocortical atrophy, increased tau burden, and greater connectomic changes affecting frontoparietal networks rather than the default mode network. SUMMARY Early-onset AD differs substantially from late-onset AD, with different phenotypic presentations, greater genetic predisposition, and differences in neuropathologic burden and topography. Early-onset AD more often presents with nonamnestic phenotypic variants that spare the hippocampi and with greater tau burden in posterior neocortices. The early-onset AD phenotypic variants involve different neural networks than typical AD. The management of early-onset AD is similar to that of late-onset AD but with special emphasis on targeting specific cognitive areas and more age-appropriate psychosocial support and education....

1 December 2005 in Cognitive and Behavioral Neurology
Verified
Journal Article
Open access
MMMario F. Mendez
Mario F. Mendez
EAEric Anderson
Eric Anderson
JSJill S Shapira
Jill S Shapira
To investigate the basis of disturbed moral judgment in patients with frontotemporal dementia (FTD). FTD is characterized by difficulty in modulating social behavior. Patients lack social propriety and may perform sociopathic acts. In addition, FTD patients often lack empathy for others. These findings suggest alterations in the nature of morality in patients with FTD. We administered an inventory of moral knowledge and two moral dilemmas to 26 patients with the frontal variant of FTD, 26 patients with Alzheimer disease (AD), and 26 normal control subjects. The FTD patients met Consensus Criteria for FTD and had corroborative frontal abnormalities on functional neuroimaging. The FTD and AD patients were comparably impaired on dementia measures. All these groups showed the retention of knowledge for moral behavior and the ability to make “impersonal” moral judgments. In contrast, the FTD patients were impaired in their ability to make immediate, emotionally based moral judgments compared with the patients with AD and the normal control subjects. These findings are consistent with an attenuation of the automatic emotional identification with others that is part of the innate moral sense. Such a disturbance may result from neurodegenerative disease affecting the ventromedial frontal cortex.

1 January 2007 in The American Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
MMMario F. Mendez
Mario F. Mendez
JSJill S. Shapira
Jill S. Shapira
AMAaron McMurtray
Aaron McMurtray
ELEliot Licht
Eliot Licht

1 June 2007 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
MMMario F. Mendez
Mario F. Mendez
JSJill S. Shapira
Jill S. Shapira
AMAaron McMurtray
Aaron McMurtray
ELEliot Licht
Eliot Licht
BMBruce L. Miller
Bruce L. Miller
Frontotemporal dementia (FTD) is a devastating neurodegenerative disease that commonly afflicts people in middle age, when they are in the prime of life.1 The early diagnosis of FTD is critical for developing management strategies and interventions for these patients. Most individuals who develop FTD manifest with new-onset behavioral symptoms,2-6 and, in the absence of a biomarker, the clinical diagnosis depends on recognizing all the core, or necessary, neuropsychiatric features of FTD.1,2

22 September 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ASAdam M. Staffaroni
Adam M. Staffaroni
MQMelanie Quintana
Melanie Quintana
BWBarbara Wendelberger
Barbara Wendelberger
HHHilary W. Heuer
Hilary W. Heuer
LRLucy L. Russell
Lucy L. Russell
ABAdam Boxer
Adam Boxer